

# Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control

Daniel J Lew\* and Sally Kornbluth

Cyclins and cyclin-dependent kinases (Cdks) are universal regulators of cell cycle progression in eukaryotic cells. Cdk activity is controlled by phosphorylation at three conserved sites, and many of the enzymes that act on these sites have now been identified. Although the biochemistry of Cdk phosphorylation is relatively well understood, the regulatory roles of such phosphorylation are, in many cases, obscure. Recent studies have uncovered new and unexpected potential roles, and prompted re-examination of previously assumed roles, of Cdk phosphorylation.

## Addresses

Department of Molecular Cancer Biology, Box 3686, Duke University Medical Center, Durham, NC 27710, USA  
\*e-mail: lew00003@mc.duke.edu

Current Opinion in Cell Biology 1996, 8:795-804

© Current Biology Ltd ISSN 0955-0674

## Abbreviations

**BIME** blocked in mitosis E  
**Cdk** cyclin-dependent kinase  
**KAP** Cdk-associated phosphatase  
**NIMA** never in mitosis A  
**PP2A** protein phosphatase 2A


## Introduction

Cyclin-dependent kinase (Cdk) activity requires binding of the Cdk to a cyclin and phosphorylation of the Cdk at a conserved threonine residue within the 'T-loop' (residue Thr161, or T161, in human Cdc2; see Fig. 1) [1]. Active, T161-phosphorylated and cyclin-bound Cdk can be inhibited by phosphorylation of two conserved residues within the catalytic cleft (residues Tyr15 [Y15] and Thr14 [T14] in human Cdc2; see Fig. 1). Although these regulatory phosphorylations were identified on, and are best characterized for, Cdc2 (the Cdk that promotes entry into mitosis; also called Cdc28 in budding yeast), similar pathways control the activity of other Cdks. Phosphorylation of chicken Cdc2 at S277 has also been described [2], but it is not clear how this affects its activity, or whether it applies to other Cdks. This review will focus on regulation at T161, Y15, and T14 of Cdc2/Cdc28 (the exact position of these residues varies between species, but in this review the same numbering will be used throughout for consistency).

### T161 phosphorylation: in search of regulation

Biochemical purification approaches were successful in identifying an abundant kinase that phosphorylates T161. Surprisingly, this kinase is itself a Cdk-cyclin complex (namely Cdk7-cyclin H) that is present in the transcription factor TFIID [3]. Apart from some reduction in activity in

Figure 1



Regulatory phosphorylation of Cdc2. Phosphorylation at T161 (single-letter code for amino acids) is necessary for Cdc2 activity, whereas phosphorylation at either T14 or Y15 (single-letter code for amino acids) inhibits activity. Kinases and phosphatases that act on these sites are indicated. The major regulatory enzymes are indicated in bold type. In some cases, indicated by question marks, it is not known whether these enzymes act on Cdc2 *in vivo*. Shaded circles and ovals represent the active forms of the proteins, and open circles and ovals represent the inactive forms.

quiescent cells, there is no evidence for variation in Cdk7 activity during the cell cycle. *In vivo* confirmation that Cdk7 is indeed a relevant T161 kinase is currently lacking, however, and studies in budding yeast demonstrated that Kin28 (the closest relative of Cdk7 in this organism; also found in TFIID) is not a T161 kinase *in vivo* or *in vitro* [4\*]. A budding yeast T161 kinase has now been identified (namely Cak1/Civ1, a 43 kDa monomeric and rather unusual kinase [5\*,6\*]), and it remains to be seen

whether Cdk7 or a Cak1 homolog is responsible for T161 phosphorylation in other organisms. T161 dephosphorylation can be catalyzed by protein phosphatase 2A (PP2A) or a newly identified phosphatase, Cdk-associated phosphatase (KAP), *in vitro* [3,7]. Once again, it is unclear whether these or other phosphatases are responsible for T161 dephosphorylation *in vivo*. Given the uncertainty regarding the enzymes that control T161 phosphorylation, we cannot yet address the question of whether this modification is ever employed in a cell cycle regulatory capacity.

### Size control in fission yeast utilizes Y15 phosphorylation

Genetic approaches in fission yeast have led to the identification of the enzymes responsible for the control of Cdc2 Y15 phosphorylation ([8–11]; reviewed in [12,13]). The kinases Wee1 and Mik1 phosphorylate Y15, whereas the phosphatases Cdc25 and Pyp3 dephosphorylate Y15 (Fig. 1). Wee1 and Cdc25 are primarily responsible for regulation of Y15 phosphorylation, whereas Mik1 and Pyp3 are minor partners whose role becomes apparent only when the major partners are compromised.

In fission yeast, a G<sub>2</sub>-phase size control operates under rapid growth conditions, such that the onset of mitosis is dependent on reaching a critical cell size. The size at mitosis was shown to be dependent on *wee1* and *cdc25* gene dosage, so that as little as a threefold increase in gene dosage has significant effects on the timing of mitosis (Wee1 delays mitosis, whereas Cdc25 advances mitosis) [8,9]. These observations demonstrated that the timing of entry into mitosis was controlled by the *cdc25:wee1* ratio. As cells grow during G<sub>2</sub> phase, the levels of *cdc25* mRNA and protein increase until mitosis is triggered, after which there is a sharp drop in both mRNA and protein abundance [14]. It has been proposed that this accumulation pattern results in a gradually increasing *cdc25:wee1* ratio during G<sub>2</sub> phase, and that the ratio becomes sufficient to trigger mitosis when cells reach the critical size. Although this model is attractive, proof will require determination of Wee1 levels (and activity) through the cell cycle. Wee1 appears to be a labile protein and, to date, it has not been technically feasible to accurately measure endogenous levels of *wee1* expression.

Recent studies have begun to address the basis for the oscillation in Cdc25 levels through the cell cycle. Cdc25 accumulates to high levels in *cdc* mutants that are blocked for cell cycle progression, whether the block is in G<sub>1</sub>, S, or G<sub>2</sub> phase [15••]. This suggests that Cdc25 accumulation during interphase depends on the total time spent in interphase, rather than the exact position in the cell cycle. Based on this, Kovelman and Russell [15••] propose that Cdc25 periodicity arises due to the rapid elimination of *cdc25* mRNA and protein that occurs during mitosis, followed by a constant rate of synthesis during interphase. In this model, size control is, in essence,


a timing mechanism: mitosis is initiated when *de novo* accumulation of Cdc25 surpasses the threshold set by the (presumed) constant Wee1 activity, yielding activation of Cdc2. A further twist in this model is provided by the observation that the extent of phosphorylation and the specific activity of Cdc25 are elevated in cells blocked in S phase compared with cells blocked in G<sub>1</sub> phase [15••]. Thus, as Cdc25 accumulates in the unperturbed cell cycle it may also be increasing in specific activity.

The mechanism behind the mitotic elimination of Cdc25 remains mysterious: it is currently unclear whether destabilization of the mRNA or protein (or both) is primarily responsible. A potentially important clue was reported recently by Nefsky and Beach [16•], who identified a protein called Pub1 that is required for efficient Cdc25 ubiquitination. Pub1 contains a domain homologous to a domain of E6-AP, a protein-ubiquitin ligase that targets p53 for degradation in human papilloma virus infected cells [17]. Like E6-AP, Pub1 forms an ubiquitin thioester that is presumed to be an intermediate in target protein ubiquitination, and Nefsky and Beach [16•] propose that Pub1 directly ubiquitinates Cdc25 and targets it for destruction. It remains to be determined whether Cdc25 stability varies through the cell cycle, and if so whether Pub1 is responsible for that regulation.

### Feedback loops for entry into mitosis

Studies on the Cdc25 proteins from *Xenopus*, humans, and fission yeast have shown that Cdc25 is hyperphosphorylated during mitosis relative to during interphase, and that this leads to a significant enhancement of its phosphatase activity (reviewed by Dunphy [13]; Fig. 2a). Similar studies on *Xenopus* and human Wee1 have also uncovered mitotic hyperphosphorylation, in this case leading to an inhibition of its kinase activity [13,18•,19,20] (Fig. 2a). Cdc2 may itself contribute to these hyperphosphorylations, but other kinases must also play a major role [19,21,22]. Recently, a Polo-like kinase (Plx1 [23]) that binds to and hyperphosphorylates Cdc25 was purified from *Xenopus*. Plx1-induced phosphorylation of Cdc25 occurs at multiple sites and generates epitopes on Cdc25 that are recognized by the mpm2 monoclonal antibody. Mpm2-binding phosphoepitopes are generated during mitosis on a number of proteins, including not only Cdc25 but also Wee1, suggesting that Plx1 may also contribute to Wee1 hyperphosphorylation in mitosis [23].

These observations reveal the potential for positive feedback loops contributing to Cdc2 activation at the G<sub>2</sub>→M transition (Fig. 2b). Such post-translational feedback control can explain early observations regarding mitosis promoting factor autoamplification [24], and is attractive in that it provides a mechanism by which to sharpen the transition into mitosis. For these reasons, positive feedback models have been popular and sometimes taken for granted in the cell cycle control field.

**Figure 2**

Models for the relationship between activation of Cdc2 and phosphorylation of its regulators (Wee1 and Cdc25) at the  $G_2 \rightarrow M$  transition. Darkly shaded shapes represent high activity of the protein, and lightly shaded shapes represent low activity of the protein. **(a)** Cdc2-cyclin complexes are inhibited through Cdc2 Tyr(Y)15 phosphorylation during interphase, and activated (so Y15 is not phosphorylated) during mitosis. Both Cdc25 (which dephosphorylates and activates Cdc2) and Wee1 (which phosphorylates and inhibits Cdc2) become hyperphosphorylated in mitosis, leading to activation of Cdc25 and repression of Wee1. **(b)** A positive feedback model proposes that, in the transition from interphase to mitosis, activation of a small amount of Cdc2 rapidly causes hyperphosphorylation of some Cdc25 and Wee1, leading to further Cdc2 activation and so on until all of the Cdc2 is active (all Y15s are dephosphorylated) and all of the Cdc25 and Wee1 proteins are hyperphosphorylated. The dashed arrows indicate that the path from Cdc2 activity to Cdc25 and Wee1 hyperphosphorylation involves intermediary steps, likely to include Polo-like kinases (see text). **(c)** An alternative model for Cdc2 activation, in which Cdc25 hyperphosphorylation is triggered by upstream regulators (likely to include both a Polo-like kinase and Cdk-cyclin complexes); activated Cdc25 then dephosphorylates and activates Cdc2. A similar model could be drawn for Wee1. **(d)** In this model, the interphase activity of Cdc25 is sufficient to cause full Cdc2 activation in the absence of Cdc25 and Wee1 hyperphosphorylation (in fission yeast, this may occur when sufficient Cdc25 protein accumulates to overcome the Wee1 present). Hyperphosphorylation of Cdc25 and Wee1 occurs downstream of Cdc2 activation and serves to 'lock' Cdc2 in the dephosphorylated state.

Although the potential for positive feedback in Cdc2 activation has been clearly established, the relevance of positive feedback as a physiological mechanism is much harder to prove. In this context, it is worth noting that a potential positive feedback loop at the G<sub>1</sub>→S transition was recently found to be irrelevant to the cell cycle in budding yeast. In that case, it had been established that transcription of the G<sub>1</sub>-phase cyclin genes *CLN1* and *CLN2* could be stimulated by the Cln1–Cdc28 and Cln2–Cdc28 kinase complexes [25,26]. As *CLN1* and *CLN2* transcripts accumulate from very low levels to maximal levels within a relatively short interval in late G<sub>1</sub> phase [27], it seemed likely that as Cln1 and Cln2 proteins accumulated they stimulated further *CLN1* and *CLN2* transcription to bring about a rapid G<sub>1</sub>→S transition. Subsequent experiments showed, however, that maximal induction of *CLN1* and *CLN2* transcripts occurs with normal kinetics regardless of whether Cln1 and Cln2 are present: transcriptional induction of *CLN1* and *CLN2* is solely dependent on a divergent cyclin, Cln3 [28•,29•]. Furthermore, the activation of Cln1–Cdc28 and Cln2–Cdc28 triggers other cell cycle processes that culminate in repression of *CLN1* and *CLN2* transcription [28•,30]. Thus, the potential for positive feedback was never realized in this system.

This example from budding yeast serves to focus attention on a possible scenario for G<sub>2</sub>→M control in which positive feedback does not play a role (Fig. 2c). In this model, some upstream regulator (Plx1 would be a good candidate) brings about full activation of Cdc25 (and/or inactivation of Wee1) with no requirement for cyclin B–Cdc2 activity (and hence no positive feedback). Cdc2 activation ensues, triggering entry into mitosis, and perhaps Cdc25 destruction. The only data that appear to contradict this model come from the observation that, in fission yeast, Cdc2 is required for Cdc25 activation [15•]. This could be simply accommodated by postulating that, as in budding yeast, an upstream cyclin–Cdk complex contributes to activation of the upstream regulator (Fig. 2c). This model would fit well with recent data from Guadagno and Newport [31•] showing that Cdk2 activity (probably in a complex with cyclin E) is required for both Cdc25 hyperphosphorylation and Cdc2 activation in cycling extracts from *Xenopus* eggs. This requirement was evident even in cytoplasmic extracts lacking nuclei, suggesting that it was unrelated to the previously characterized Cdk2 requirement for DNA replication.

Other scenarios can also be envisaged. For instance, it may be that the basal interphase activity of Cdc25 is sufficient to provoke full Cdc2 activation, leading to subsequent hyperphosphorylation of Cdc25 (Fig. 2d). In this model, Cdc25 activation in mitosis would simply constitute an insurance mechanism to ensure that Cdc2 remains active until the cyclin is degraded. Distinguishing between the different models will require examination of the effects of preventing Cdc25 or Wee1 hyperphosphorylation (without perturbing basal activity) *in vivo*.

### Developmental regulation of the cell cycle

Elegant studies in *Drosophila* embryos have shown that different cell cycle regulators become rate-limiting for cell cycle progression at various stages of development (reviewed by Edgar [32•]). In particular, transcription of *cdc25* (called *string* in *Drosophila*) is rate-limiting for the timing of many postblastoderm mitoses, and the correct pattern of *cdc25* transcription is therefore critical for morphogenesis during development. *cdc25* has a large (>40 kb) promoter region with multiple elements that respond locally to various pattern formation genes [33]. This suggests that the positional information embodied in the complex expression patterns of these genes is translated into a particular spatiotemporal pattern of cell division through regulation of *cdc25* transcription.

### Checkpoint control: DNA replication

Seven years ago, Enoch and Nurse [34] reported that certain mutations affecting Cdc2 Y15 phosphorylation in fission yeast could override the checkpoint control that delays entry into mitosis in response to incomplete DNA replication. This result was the first to implicate Cdc2 as a target of checkpoint controls, and suggested that the DNA-replication checkpoint might inhibit entry into mitosis simply by tilting the balance of Cdc25 and Wee1 activities in favor of Cdc2 phosphorylation. However, cells lacking both Wee1 and Cdc25 maintained the ability to respond to incomplete DNA replication by delaying entry into mitosis, showing that neither Wee1 nor Cdc25 could be the sole target of the checkpoint control [35]. Thus, if Cdc2 Y15 phosphorylation is regulated by the checkpoint, there must be several regulatory inputs affecting both the major and the minor enzymes that act on Cdc2 Y15.

### Cdc2 Y15 phosphorylation is not always required for checkpoint function

In the past few years, considerable effort has been devoted to studies of the mechanisms underlying checkpoint arrest of the cell cycle. One conclusion from these studies is that the requirement for an intact Cdc2 Y15 phosphorylation pathway varies from species to species. In fission yeast, the ability to phosphorylate Cdc2 Y15 is absolutely required for inhibition of mitosis in cells that have not completed DNA replication [10,34]. In contrast, recent studies in *Xenopus* egg extracts [36•], human cells [37•], and *Aspergillus nidulans* [38•], combined with earlier studies in budding yeast [39,40], suggest that nonphosphorylatable Cdc2 or Cdc28 mutants cannot override a checkpoint arrest induced by drugs that prevent DNA replication. These studies establish that there must exist some non-Y15-related mechanism(s) whereby the checkpoint can prevent entry into mitosis.

Intriguingly, the ability to phosphorylate Cdc2 Y15 was critical for the checkpoint-induced delay of mitosis in *A. nidulans* cells exposed to low levels of drugs sufficient


to slow, but not block, DNA replication [38\*]. In addition, human cells expressing the nonphosphorylatable Cdc2 mutant displayed a significant loss of viability following addition of the drug, suggesting that the checkpoint was at least partially compromised (C McGowan, personal communication). In these cases, it appears that the ability to phosphorylate Y15 is critical for checkpoint operation when DNA replication is merely delayed, but is perhaps dispensable when DNA replication is completely blocked. These data have been interpreted [38\*] as evidence for two distinct checkpoint pathways responding to incomplete DNA replication: one pathway which has a sensitive detection threshold and requires Cdc2 Y15 phosphorylation; and another which is relatively insensitive (hence large amounts of drugs are required to trigger this pathway) and which operates independently of Y15 phosphorylation (Fig. 3a). The species specificity then arises because different pathways are prevalent in different cells: fission yeast use only the Y15-dependent pathway, *Aspergillus* and human cells use both, and budding yeast use only the Y15-independent pathway.

Although this model accounts for all of the observations, we believe that an alternative and perhaps simpler model is also consistent with the available data (Fig. 3b; a similar model has been discussed by Kumagai and Dunphy [36\*]). In this model, the checkpoint operates exclusively through the Y15-independent pathway(s) in all organisms. This pathway responds in a graded fashion to the checkpoint stimulus (incomplete DNA replication), and this graded signal leads to inhibition of Cdc2 through a mechanism that does not involve regulation of Y15 phosphorylation.

The species specificity in this model arises due to the extent to which Cdc2 Y15 phosphorylation is prevalent in the unperturbed cycle (Fig. 3b). A G<sub>2</sub>-phase delay introduced by a Y15-independent checkpoint mechanism would allow Y15-phosphorylated Cdc2 to accumulate due to the continued action of constitutively active Wee1-like kinases. This Y15 phosphorylation would be expected to assist in the suppression of Cdc2 activity, and the degree of assistance provided would depend on the prevalence of Cdc2 Y15 phosphorylation in different cells. In fission

**Figure 3**

Two models for the operation of the DNA-replication checkpoint in different species. **(a)** There are two separate checkpoint mechanisms, one of which modulates the enzymes that control Tyr(Y)15 phosphorylation and the other of which does not. Fission yeast use the first mechanism (and hence require Cdc2 Y15 phosphorylation for checkpoint function), whereas budding yeast use the second (and hence have a functional checkpoint even in the absence of Cdc28 Y15 phosphorylation). Other organisms have a mixed checkpoint that uses both pathways. **(b)** All cells respond to incomplete DNA replication through a pathway that does not affect the enzymes that control Cdc2 Y15 phosphorylation (i.e. through a Y15-independent mechanism). In addition, Y15 phosphorylation occurring normally as part of the cell cycle assists the checkpoint in preventing entry into mitosis. The prevalence of Y15 phosphorylation varies between species (indicated by the thickness of the arrows) and therefore provides different degrees of assistance to the checkpoint.



yeast, Y15 phosphorylation is thought to occur at high stoichiometry on Cdc2–Cdc13 complexes during interphase, and cells that cannot phosphorylate Cdc2 Y15 undergo an extreme and catastrophic acceleration of mitosis [10]. In budding yeast, however, Y15 phosphorylation is thought to occur at low stoichiometry (if at all) on Cdc28–Clb complexes, and cells that cannot phosphorylate Cdc28 Y15 do not exhibit any change in the kinetics of mitosis [39–42]. In *Aspergillus* and human cells, an intermediate situation may exist, wherein cells expressing the Cdc2 nonphosphorylatable mutant undergo a mild acceleration of mitosis [37\*,38\*].

These species-specific differences suggest that checkpoint pathways in different organisms may have evolved in environments with differing levels of Cdc2 Y15 phosphorylation. In fission yeast, the prevalence of Y15 phosphorylation might allow a checkpoint pathway to prevent entry into mitosis via inhibitors that would be insufficient or ineffective when Y15 is dephosphorylated. In contrast, a checkpoint-induced inhibitor in budding yeast would have to operate in the absence of significant Y15 phosphorylation. Therefore, the differing ability of nonphosphorylatable Cdc2 mutants to override a checkpoint arrest in different species could be explained by the degree to which tyrosine phosphorylation would be expected to assist in maintaining the checkpoint arrest in these species. In the simplest case, a single ancestral checkpoint pathway may have adapted to produce different ‘strengths’ of inhibition in the different organisms (Fig. 3b).

#### Regulation of Cdc2 Y15 phosphorylation by the checkpoint

This model focuses attention on the question of whether or not there is ever a situation in which the DNA-replication checkpoint modulates the enzymes that control Y15 phosphorylation. This question has been addressed in *Xenopus* egg extracts, with apparently contradictory results. In one study, Smythe and Newport [43] found that Wee1-like activities in checkpoint-arrested extracts were elevated fivefold to tenfold compared with those in cycling extracts. In contrast, Kumagai and Dunphy [36\*] found no difference in such activities between checkpoint-arrested and nonarrested extracts. The assay in both cases was initiated by adding tagged recombinant cyclin proteins to different extracts. These added cyclins formed complexes with the free Cdc2 in the extracts and therefore created fresh substrate for Wee1-like kinases. The initial rate of phosphorylation of this tagged cyclin–Cdc2 substrate by Wee1-like kinases was then used to estimate the total Cdc2 Y15-directed tyrosine kinase activity in the extracts.

One difficulty in this kind of assay is that the tagged substrate becomes fully phosphorylated within a short time. Kumagai and Dunphy [36\*] showed full phosphorylation of the substrate at five minutes, whereas Smythe and Newport’s substrates [43] still appeared to be in the initial

phase of phosphorylation at ten minutes. This is probably explained by the fact that Smythe and Newport added much more tagged cyclin (2–3  $\mu\text{M}$  final concentration) than Kumagai and Dunphy (30–40 nM final concentration). As their substrate was phosphorylated so rapidly, it may have been difficult for Kumagai and Dunphy [36\*] to detect an enhancement of the initial rate of phosphorylation. Another experimental difference was that Smythe and Newport [43] used cycling extracts with ongoing protein (and cyclin) synthesis, whereas Kumagai and Dunphy [36\*] employed interphase extracts containing cycloheximide. Conceivably, a checkpoint-mediated mechanism inducing Wee1-like kinases might decay in the absence of protein synthesis, and would therefore be missed in the Kumagai and Dunphy protocol. The cycloheximide-containing extracts did exhibit a robust checkpoint, however, so protein synthesis is not essential for all checkpoint function, and would have to be required specifically for the Y15-regulatory pathway.

These considerations suggest the possibility that a real checkpoint-induction of Wee1-like kinases may have been obscured in the experiments of Kumagai and Dunphy [36\*]. It is also possible, however, that they are correct and that there is no induction of Wee1-like kinases by the DNA-replication checkpoint. Conceivably, a misleading apparent induction of Wee1-like kinases in the experiments of Smythe and Newport [43] may have resulted from the Y15-independent checkpoint mechanism proposed by Kumagai and Dunphy [36\*]. In one scenario, the large amount of cyclin added by Smythe and Newport may have led to a highly active cyclin–Cdc2 complex in the extract during the 10-minute assay. As mentioned above, mitotic hyperphosphorylation is known to repress Wee1 activity. Thus, the bolus of active Cdc2 generated at the beginning of the assay may have had an inhibitory effect on Wee1-like kinases in the extract. In the checkpoint-arrested extract, the Y15-independent inhibitory pathway may have prevented (or slowed) the activation of Cdc2 by added cyclin, so that an uninhibited Wee1-like activity would be maintained during the short assay time interval. Compared with the artificially repressed activity in the nonarrested extract, this might falsely appear to be a checkpoint stimulation of Wee1-like kinases.

Another experimental difference between the two studies was that Smythe and Newport [43] used a GST (glutathione-S-transferase)-tagged sea urchin cyclin produced in bacteria, whereas Kumagai and Dunphy [36\*] used a His-tagged human cyclin produced in insect cells. A puzzling property of the sea urchin cyclin was that its addition to checkpoint-arrested extracts promoted override of the checkpoint and entry into mitosis. Had the sea urchin cyclin been the one that failed to reveal any difference between checkpoint-arrested and nonarrested extracts, we might with some confidence have ascribed that result to an aberrant property of this particular cyclin.

However, it is much harder to explain the finding that the use of this cyclin did in fact reveal a significant checkpoint induction of Wee1-like kinases.

The question of whether Wee1-like kinases are induced by the DNA-replication checkpoint was also addressed in human cells by McGowan and Russell [18\*]. They found that the activity of the major assayable Wee1-like kinase in soluble HeLa cell lysates was identical whether the lysates were prepared from cycling or checkpoint-arrested cells. Thus, at least this kinase did not appear to be induced by the checkpoint.

In addition to measuring the effect of the checkpoint on Wee1-like kinases in the extract, Kumagai and Dunphy [36\*] attempted to measure checkpoint effects on the activity of Cdc25-like phosphatases. They observed no difference between checkpoint-arrested and cycling extracts, and concluded that regulation of Cdc25-like phosphatases by the checkpoint was unlikely. However, the activity in their assay was very low, and a checkpoint-mediated inhibition of Cdc25-like factors may have been undetectable. In summary, the available data do not permit a definitive conclusion as to whether Cdc2 Y15 directed enzymes are regulatory targets for the DNA-replication checkpoint.

If regulation of Cdc2 Y15 phosphorylation does not mediate the checkpoint-induced delay in mitosis, how does the checkpoint work? An elegant experiment by Kumagai and Dunphy [36\*] suggested that a titratable Cdc2 inhibitor might play a role in *Xenopus* extracts. They first showed that checkpoint-arrested extracts could inhibit added cyclin-Cdc2 complexes that were sufficient to induce mitosis in the absence of a checkpoint, even if the added Cdc2 was not phosphorylatable at Y15 (or T14). This demonstrated the existence of a Y15-independent checkpoint pathway (see above). They then showed that the checkpoint arrest could be overridden by adding sufficient quantities of cyclin-Cdc2 complexes containing a catalytically inert mutant of Cdc2. This suggested that a titratable inhibitor in the extracts may have bound to the added (inactive) complexes, releasing the endogenous complexes to promote entry into mitosis. Recently, a large membrane-associated Cdc2 inhibitor was described in *Xenopus* egg extracts [44\*], but it is not known whether this inhibitor is induced by the checkpoint.

In *Aspergillus*, the BIME (blocked in mitosis E) protein is required for an effective checkpoint [38\*,45]. One role for BIME is apparently to suppress the activity of the protein kinase NIMA (never in mitosis A) [38\*], which is essential for entry into mitosis in *Aspergillus*. Whether this constitutes the relevant (or only) checkpoint-related role of BIME remains to be determined. Although these observations provide tantalizing clues, we do not yet have a clear picture of how this checkpoint mediates cell cycle arrest.

### Checkpoint control: DNA damage

Carr and colleagues [46,47] have argued that, unlike the DNA-replication checkpoint, the checkpoint responding to DNA damage does not require Y15 phosphorylation. This conclusion was based on experiments showing that fission yeast strains (including *wee1* mutants and *cdc2* mutants) that were unable to sustain a DNA-replication checkpoint could, nevertheless, delay mitosis in response to DNA damage. These strains were partially impaired in their ability to inhibit Cdc2 through Y15 phosphorylation, suggesting that the DNA-damage checkpoint could delay mitosis even in the absence of such phosphorylation. However, N Rhind and P Russell (personal communication) recently found that in *wee1 mik1* double mutants (which are completely unable to phosphorylate Y15), the DNA damage checkpoint response is severely impaired. This demonstrates that Cdc2 Y15 phosphorylation is required for the DNA-damage checkpoint to operate in fission yeast, although the requirement appears to be less stringent than for the DNA-replication checkpoint. In human cells, Y15 phosphorylation is important for the delay of mitosis by the DNA-damage checkpoint, but some delay still occurs in cells containing the nonphosphorylatable Cdc2 mutant [37\*]. In budding yeast, the DNA-damage checkpoint does not require Cdc28 Y15 phosphorylation [39–42]. Thus, a species-specific pattern of Y15-phosphorylation requirements applies to the DNA-damage checkpoint as well as to the DNA-replication checkpoint. The key question of whether the DNA-damage checkpoint causes regulation of Wee1- or Cdc25-like activities has not yet been addressed.

### Checkpoint control: morphogenesis

In budding yeast, a nonphosphorylatable Cdc28 mutant does not appreciably affect cell cycle kinetics, and does not affect the ability of the DNA-damage and DNA-replication checkpoints to delay cell cycle progression [39–42]. It seems likely that Cdc28 is not phosphorylated to a significant stoichiometry during the unperturbed cell cycle in this organism. However, Cdc28 tyrosine phosphorylation is detectable in cells arrested in S phase [39], and Wee1 [41] and Cdc25 [48] homologs have been identified in budding yeast. These findings raised the question of whether the Y15-phosphorylation pathway in this organism is vestigial or whether it functions in some other physiological setting.

It has been known for some time that changes in the growth environment (e.g. shifts in temperature [49] or osmolarity [50]) of budding yeast provoke a stress response that involves a transient depolarization of the actin cytoskeleton, leading to delays in bud formation. Despite these delays, the cell cycle in stressed cells remains well coordinated with bud formation. Recently, a morphogenesis checkpoint was described in budding yeast that delays nuclear division in cells that have failed to form a suitable bud [51\*\*]. It was proposed that this checkpoint

is responsible for adjusting the cell cycle of stressed cells to prevent the formation of binucleate cells.

Strikingly, Cdc28 Y15 phosphorylation was found to be essential for the ability of the morphogenesis checkpoint to delay nuclear division [51\*\*]. Indeed, the timing of nuclear division in cells with depolarized actin was found to be very sensitive to the gene dosage of the *wee1* and *cdc25* homologs [52]. Thus, as in fission yeast, the cell cycle in budding yeast cells with depolarized actin displays a long G<sub>2</sub> phase, and the timing of nuclear division is determined by the *cdc25:wee1* ratio. To explain these observations, it was proposed that the morphogenesis checkpoint regulated the Wee1 and/or Cdc25 homologs in response to defects in bud formation [52]. As for the other checkpoints, however, direct regulation of these activities remains to be demonstrated.

### T14 phosphorylation: Y15 assistant?

Phosphorylation of Cdc2 T14 has been observed in metazoans [2,53,54]. Recently, T14 phosphorylation was also detected in fission yeast [55], but it is unclear whether it ever occurs at high enough stoichiometry to serve a cell cycle regulatory role in this organism. Mutation of *cdc2* so that the protein cannot be phosphorylated at T14 does not cause any cell-cycle or checkpoint perturbation in any system analyzed thus far. However, double mutants that cannot be phosphorylated at either T14 or Y15 often result in an enhanced defect compared with defects produced by mutations at Y15 alone [53,56]. These findings suggest that T14 and Y15 phosphorylation performs similar roles, yielding a double block to Cdc2 activation. One reason for employing a double block may be that the most abundant protein phosphatases in the cell are specific for either serine/threonine- or tyrosine-phosphorylated proteins. The probability that such phosphatases might accidentally (and perhaps catastrophically) activate Cdc2 is greatly reduced by the requirement that both T14 and Y15 be dephosphorylated. Thus, activation of Cdc2 would depend uniquely on the highly specific dual-specificity threonine/tyrosine phosphatase, Cdc25.

Although Cdc25 is able to dephosphorylate both T14 and Y15 [57,58], Wee1 is only able to phosphorylate Y15 of Cdc2 [59,60]. A dual-specificity kinase capable of promoting phosphorylation of both T14 and Y15 was found to be associated with membranes in *Xenopus* egg extracts [61,62], and is almost certainly the same as the kinase Myt1 which was identified in a PCR search for Wee1 homologs in *Xenopus* [63\*]. Like Wee1, Myt1 is hyperphosphorylated and inhibited during mitosis [63\*].

Myt1 contains a putative transmembrane domain [63\*], and a human Myt1 homolog resides primarily in the endoplasmic reticulum (H Piwnicka-Worms, personal communication). In contrast, Wee1 resides in the nucleus, at least when overexpressed [18\*]. This suggests that the two

kinases may be phosphorylating different populations of Cdc2. This idea is particularly attractive in light of the finding that different cyclin B isoforms (that presumably form the Cdc2 complexes that are targets for regulation by Wee1 and Myt1) display distinct subcellular localizations in human cells [64\*\*].

### Conclusions

The past year or two have produced advances on many fronts in the field of Cdk regulation. Novel kinases that phosphorylate Cdc2 at T161 (Cak1/Civ1) and T14/Y15 (Myt1) have been identified and provide new avenues along which to study Cdc2 regulation. Cdc2 phosphorylation independent mechanisms have been discovered to play a key role in the DNA-replication checkpoint in many, if not all, cells. A morphogenesis checkpoint may explain the elusive nature of Cdc28 Y15 phosphorylation in budding yeast, and new pieces have been added to the story of size control in fission yeast.

Moving from the study of what can happen in laboratory assays to the study of what *does* happen in a physiological setting poses significant challenges for the coming years. As our understanding of cell cycle control increases, the subtlety and sophistication of experimental analyses are growing. Problems such as the basis of size control, the role of positive feedback loops in cell cycle control, and the mechanisms whereby checkpoints affect cell cycle progression are not easy to answer, but there is every reason to hope that the solutions will emerge from a concerted attack by the highly active cell cycle community.

### Acknowledgements

We thank C McGowan, S Osmani, H Piwnicka-Worms, and P Russell for communicating results before publication, and J Pines and P Russell for critical comments on the text. Work in the authors' laboratories was supported by a Special Fellowship from the Leukemia Society of America and a grant from the American Cancer Society (to S Kornbluth) and by grants from the National Institutes of Health and the Searle Scholars Program/The Chicago Community Trust (to DJ Lew).

### References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
  - of outstanding interest
1. Solomon MJ: **Activation of the various cyclin/cdc2 protein kinases.** *Curr Opin Cell Biol* 1993, **5**:180-186.
  2. Krek W, Nigg E: **Differential phosphorylation of vertebrate p34<sup>cdc2</sup> kinase at the G1/S and G2/M transitions of the cell cycle: identification of major phosphorylation sites.** *EMBO J* 1991, **10**:305-316.
  3. Nigg EA: **Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control?** *Curr Opin Cell Biol* 1996, **8**:312-317.
  4. Cismowski MJ, Laff GM, Solomon MJ, Reed SI: **KIN28 encodes a C-terminal domain kinase that controls mRNA transcription in *Saccharomyces cerevisiae* but lacks cyclin-dependent kinase-activating kinase (CAK) activity.** *Mol Cell Biol* 1995, **15**:2983-2992.

This paper demonstrates that the closest budding yeast homolog of Cdk7, Kin28, does not function as a Cdc28-activating kinase either *in vitro* or



*in vivo*. *kin28* mutants block transcription (presumably reflecting a role for Kin28 in TFIH activity) but allow continued Cdc28 phosphorylation even after cyclin synthesis has ceased, showing that the Cdk-activating kinase can phosphorylate monomeric Cdc28 in this organism.

5. Thuret J-Y, Valay J-G, Faye G, Mann C: Civ1 (**CAK in vivo**), a novel Cdk-activating kinase. *Cell* 1996, **86**:565-576.  
A Cdk activating kinase activity was found to copurify with cyclin-Cdc28 complexes from yeast, and was identified as a multicopy suppressor of *kin28* mutations. See also annotation [6\*].
6. Kaldis P, Sutton A, Solomon MJ: **The Cdk-activating kinase (CAK) from budding yeast**. *Cell* 1996, **86**:553-564.  
This paper reports the successful purification of a Cdk-activating kinase (CAK) activity from budding yeast lysates. Together with [5\*], this study provides strong evidence that this kinase (called Cak1) is the physiological CAK in yeast. Cak1 is a 43 kDa protein that is surprisingly highly diverged from other known protein kinases.
7. Poon RY, Hunter T: **Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin**. *Science* 1995, **270**:90-93.
8. Russell P, Nurse P: ***cdc25+* functions as an inducer in the mitotic control of fission yeast**. *Cell* 1986, **45**:145-153.
9. Russell P, Nurse P: **Negative regulation of mitosis by *wee1+*, a gene encoding a protein kinase homolog**. *Cell* 1987, **45**:145-153.
10. Lundgren K, Walworth N, Booher R, Dembski M, Kirschner M, Beach D: ***mik1* and *wee1* cooperate in the inhibitory tyrosine phosphorylation of *cdc2***. *Cell* 1991, **64**:1111-1122.
11. Millar JB, Lenaers G, Russell P: ***Pyp3* PTPase acts as a mitotic inducer in fission yeast**. *EMBO J* 1992, **11**:4933-4941.
12. Atherton-Fessler S, Hannig G, Piwnicka-Worms H: **Reversible tyrosine phosphorylation and cell cycle control**. *Semin Cell Biol* 1993, **4**:433-442.
13. Dunphy WG: **The decision to enter mitosis**. *Trends Cell Biol* 1994, **4**:202-207.
14. Moreno S, Nurse P, Russell P: **Regulation of mitosis by cyclic accumulation of *p80cdc25* mitotic inducer in fission yeast**. *Nature* 1990, **344**:549-552.
15. Kovelman R, Russell P: **Stockpiling of *Cdc25* during a DNA replication checkpoint arrest in *Schizosaccharomyces pombe***. *Mol Cell Biol* 1996, **16**:86-93.  
This interesting paper shows that the periodicity of *cdc25* mRNA arises as a result of periodic destruction of *cdc25* mRNA in mitosis, that Cdc25 protein can have at least three distinct activity states depending on the level of phosphorylation, and that Cdc2 activity is required for full activation of Cdc25.
16. Nefsky B, Beach D: ***Pub1* acts as an E6-AP-like protein ubiquitin ligase in the degradation of *cdc25***. *EMBO J* 1996, **15**:1301-1312.  
Following the accidental discovery of Pub1 in a screen for tyrosine kinases, the authors noticed that *pub1* mutants affected size control in fission yeast. Following this lead, they examined the connection between Pub1 and regulators of Cdc2 Y15 phosphorylation, and found that Pub1 was required for Cdc25 ubiquitination and degradation.
17. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: **The HPV16 E6 and E6-AP complex functions as a ubiquitin protein ligase in the ubiquitination of p53**. *Cell* 1993, **75**:495-505.
18. McGowan CH, Russell P: **Cell cycle regulation of human WEE1**. *EMBO J* 1995, **14**:2166-2175.  
This careful study documents the inhibitory hyperphosphorylation of Wee1 during mitosis in HeLa cells, but finds no evidence for the regulation of Wee1 by the DNA-replication checkpoint.
19. Mueller PR, Coleman TR, Dunphy WG: **Cell cycle regulation of a *Xenopus* Wee1-like kinase**. *Mol Biol Cell* 1995, **6**:119-134.
20. Watanabe N, Broome M, Hunter T: **Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle**. *EMBO J* 1995, **14**:1878-1891.
21. Izumi T, Maller JL: **Phosphorylation and activation of the *Xenopus* Cdc25 phosphatase in the absence of Cdc2 and Cdk2 kinase activity**. *Mol Biol Cell* 1995, **6**:215-226.
22. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G: **Phosphorylation and activation of human *cdc25-C* by *cdc2*-cyclin B and its involvement in the self-amplification of MPF at mitosis**. *EMBO J* 1993, **12**:53-63.

23. Kumagai A, Dunphy WG: **Purification and molecular cloning of P1x1, a *cdc25* regulatory kinase from *Xenopus* egg extracts**. *Science* 1996, **273**:1377-1380.
24. Cyert MS, Kirschner MC: **Regulation of MPF activity *in vitro***. *Cell* 1988, **53**:185-195.
25. Cross FR, Tinkelenberg AH: **A potential positive feedback loop controlling *CLN1* and *CLN2* gene expression at the start of the yeast cell cycle**. *Cell* 1991, **65**:875-883.
26. Dirick L, Nasmyth K: **Positive feedback in the activation of G1 cyclins in yeast**. *Nature* 1991, **351**:754-757.
27. Wittenberg C, Sugimoto K, Reed SI: **G1-specific cyclins of *Saccharomyces cerevisiae*: cell cycle periodicity, regulation by mating pheromone and association with the p34<sup>CDC28</sup> protein kinase**. *Cell* 1990, **62**:225-237.
28. Stuart D, Wittenberg C: ***CLN3*, not positive feedback, determines the timing of *CLN2* transcription in cycling cells**. *Genes Dev* 1995, **9**:2780-2794.  
This paper and [29\*\*] report a series of extremely ingenious and well designed experiments which aimed to dissect the relationship between the activity of different G<sub>1</sub>-phase cyclin-Cdc28 complexes and the transcription of G<sub>1</sub>-phase cyclin genes in yeast. In contrast to the prevailing positive feedback model, the authors conclude that transcriptional activation of *CLN1* and *CLN2* is triggered solely by Cln3-Cdc28 complexes.
29. Dirick L, Bohm T, Nasmyth K: **Roles and regulation of Cln-Cdc28 kinases at the start of the cell cycle of *Saccharomyces cerevisiae***. *EMBO J* 1995, **14**:4803-4813.  
See annotation [28\*\*].
30. Amon A, Tyers M, Futcher B, Nasmyth K: **Mechanisms that help the yeast cell cycle clock tick: G2 cyclins transcriptionally activate G2 cyclins and repress G1 cyclins**. *Cell* 1993, **74**:993-1007.
31. Guadagno TM, Newport JW: **Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity**. *Cell* 1996, **84**:73-82.  
This paper shows that the Cdk inhibitor p21 inhibits entry into mitosis in *Xenopus* egg extracts, at concentrations that directly inhibit Cdk2, but not Cdc2. The block to mitosis is accompanied by accumulation of Y15-phosphorylated Cdc2-cyclin complexes, suggesting a requirement for Cdk2 in order to dephosphorylate Cdc2.
32. Edgar B: **Diversification of cell cycle controls in developing embryos**. *Curr Opin Cell Biol* 1995, **7**:815-824.  
A lucid and well written account of the different rate-limiting steps in cell cycle progression that predominate in different cells of the developing *Drosophila* embryo.
33. Edgar BA, Lehman DA, O'Farrell PH: **Transcriptional regulation of string (*cdc25*): a link between developmental programming and the cell cycle**. *Development* 1994, **120**:3131-3143.
34. Enoch T, Nurse P: **Mutation of fission yeast cell cycle control genes abolishes dependence of mitosis on DNA replication**. *Cell* 1990, **60**:665-673.
35. Enoch T, Carr AM, Nurse P: **Fission yeast genes involved in coupling mitosis to completion of DNA replication**. *Genes Dev* 1992, **6**:2035-2046.
36. Kumagai A, Dunphy WG: **Control of the Cdc2/cyclin B complex in *Xenopus* egg extracts arrested at a G2/M checkpoint with DNA synthesis inhibitors**. *Mol Biol Cell* 1995, **6**:199-213.  
The main interest of this paper is a set of careful experiments with nonphosphorylatable Cdc2 mutants that reveal the existence of a Y15-independent pathway which blocks mitosis in checkpoint-arrested extracts. A model involving a putative Cdk inhibitor is proposed (see [44\*]).
37. Jin P, Gu Y, Morgan DO: **Role of inhibitory CDC2 phosphorylation in radiation induced G2 arrest in human cells**. *J Cell Biol* 1996, **134**:963-970.  
A study in which a human cell line is created containing a *cdc2* allele, with an inducible promoter, whose encoded protein cannot be phosphorylated at T14 and Y15. Expression of this allele does not override the arrest resulting from a block in DNA replication, but it does significantly shorten the cell cycle delay induced by DNA-damage.
38. Ye XS, Fincher RR, Tang A, O'Donnell K, Osmani SA: **Two S-phase checkpoint systems, one involving the function of both BIME and Tyr15 phosphorylation of p34<sup>cdc2</sup>, inhibit NIMA and prevent premature mitosis**. *EMBO J* 1996, **15**:3599-3610.  
A complex paper presenting interesting data on the requirements for the function of the DNA-replication checkpoint in *A. nidulans*. A Cdc2 mutant that cannot be phosphorylated at T14 or Y15 overrides the checkpoint delay induced by low doses of replication inhibitors, while concurrent inacti-

ion of *bimE* is necessary to override the checkpoint delay induced by high doses of replication inhibitors. The authors suggest that Cdc2 phosphorylation leads to decreased synthesis of NIMA, whereas BIME prevents phosphorylation-dependent activation of NIMA; together, these two actions keep NIMA turned off in checkpoint-arrested cells.

- Amon A, Surana U, Muroff I, Nasmyth K: **Regulation of p34CDC28 tyrosine phosphorylation is not required for entry into mitosis in *S. cerevisiae*.** *Nature* 1992, 355:368-371.
- Sorger PK, Murray AW: **S-phase feedback control in budding yeast independent of tyrosine phosphorylation of p34cdc28.** *Nature* 1992, 355:365-368.
- Booher RN, Deshaies RJ, Kirschner MW: **Properties of p34CDC28 in response to G1 and G2 cyclins.** *EMBO J* 1993, 12:3417-3426.
- Stueland CS, Lew DJ, Cismowski MJ, Reed SI: **Full activation of p34cdc28 histone H1 kinase activity is unable to promote entry into mitosis in checkpoint-arrested cells of the yeast *Saccharomyces cerevisiae*.** *Mol Cell Biol* 1993, 13:3744-3755.
- Smythe C, Newport JW: **Coupling of mitosis to the completion of S phase in *Xenopus* occurs via modulation of the tyrosine kinase that phosphorylates p34cdc2.** *Cell* 1992, 68:787-797.
- Lee TH, Kirschner MW: **An inhibitor of p34cdc2/cyclin B that regulates the G2/M transition in *Xenopus* extracts.** *Proc Natl Acad Sci USA* 1996, 93:352-356.
- Identification of a stoichiometric inhibitor of Cdc2 that is associated with membranes in *Xenopus* extracts.
- James SW, Mirabito PM, Scacheri PC, Morris NR: **The *Aspergillus nidulans* bimE (blocked-in-mitosis) gene encodes multiple cell cycle functions involved in mitotic checkpoint control and mitosis.** *J Cell Sci* 1995, 108:3485-3499.
- Barbet NC, Carr AM: **Fission yeast wee1 protein kinase is not required for DNA damage-dependent mitotic arrest.** *Nature* 1993, 364:824-827.
- Sheldrick KS, Carr AM: **Feedback controls and G2 checkpoints: fission yeast as a model system.** *Bioessays* 1993, 15:775-782.
- Russell P, Moreno S, Reed SI: **Conservation of mitotic controls in fission and budding yeast.** *Cell* 1989, 57:295-303.
- Lillie SH, Brown SS: **Immunofluorescence localization of the unconventional myosin, Myo2p, and the putative kinesin-related protein, Smy1p, to the same regions of polarized growth in *Saccharomyces cerevisiae*.** *J Cell Biol* 1994, 125:825-842.
- Chowdhury S, Smith KW, Gustin MC: **Osmotic stress and the yeast cytoskeleton: phenotype-specific suppression of an actin mutation.** *J Cell Biol* 1992, 118:561-571.
- Lew DJ, Reed SI: **A cell cycle checkpoint monitors cell morphogenesis in budding yeast.** *J Cell Biol* 1995, 129:739-749.

This paper describes a novel cell cycle checkpoint that comes into play when spindle formation is compromised in yeast. Mutants that prevent polarization of actin cytoskeleton are shown to undergo a cell cycle delay following DNA replication but prior to nuclear division. The delay is caused by a delayed

induction of Clb-Cdc28 activity, primarily due to Y15 phosphorylation of Cdc28.

52. Sia RAL, Herald HA, Lew DJ: **Cdc28 tyrosine phosphorylation and the morphogenesis checkpoint in budding yeast.** *Mol Biol Cell* 1996, in press.
53. Norbury C, Blow J, Nurse P: **Regulatory phosphorylation of the p34<sup>cdc2</sup> protein kinase in vertebrates.** *EMBO J* 1991, 10:3321-3329.
54. Solomon MJ, Lee T, Kirschner MW: **Role of phosphorylation in p34cdc2 activation: identification of an activating kinase.** *Mol Biol Cell* 1992, 3:13-27.
55. Haese GJD, Walworth N, Carr AM, Gould KL: **The Wee1 protein kinase regulates T14 phosphorylation of fission yeast Cdc2.** *Mol Biol Cell* 1996, 6:371-385.
56. Krek W, Nigg E: **Mutations of p34<sup>cdc2</sup> phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34<sup>cdc2</sup> kinase activation in vertebrates.** *EMBO J* 1991, 10:3331-3341.
57. Kumagai A, Dunphy WG: **The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system.** *Cell* 1991, 64:903-914.
58. Millar JBA, McGowan CH, Lenaers G, Jones R, Russell P: **p80<sup>cdc25</sup> mitotic inducer is the tyrosine phosphatase that activates p34<sup>cdc2</sup> kinase in fission yeast.** *EMBO J* 1991, 10:4301-4309.
59. McGowan CH, Russell P: **Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15.** *EMBO J* 1993, 12:75-85.
60. Parker LL, Piwnicka-Worms H: **Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase.** *Science* 1992, 257:1955-1957.
61. Kornbluth S, Sebastian B, Hunter T, Newport J: **Membrane localization of the kinase which phosphorylates p34cdc2 on threonine 14.** *Mol Biol Cell* 1994, 5:273-282.
62. Atherton-Fessler S, Liu F, Gabrielli B, Lee MS, Peng CY, Piwnicka-Worms H: **Cell cycle regulation of the p34cdc2 inhibitory kinases.** *Mol Biol Cell* 1994, 5:989-1001.
63. Mueller PR, Coleman TR, Kumagai A, Dunphy WG: **Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15.** *Science* 1995, 270:86-90.
- A PCR-based screen identifies the Wee1 homolog Myt1, which contains a putative transmembrane domain. Myt1 phosphorylates both T14 and Y15 of Cdc2, is membrane-associated, and is inhibited during mitosis.
64. Jackman M, Firth M, Pines J: **Human cyclins B1 and B2 are localized to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus.** *EMBO J* 1995, 14:1646-1654.

This paper documents the distinct subcellular localizations of two highly related cyclins of the same class, namely cyclins B1 and B2. The localization of these cyclins to structures that undergo dramatic reorganizations during the cell cycle is suggestive that individual cyclins are specialized for inducing localized changes in distinct structures.